New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
This new histological subtype data confirms DecisionDx-Melanoma’s clinical value across the spectrum of melanoma Castle Biosciences will also present validation data on its atopic dermatitis pipeline test FRIENDSWOOD, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it is presenting data on its DecisionDx®-Melanoma test and its pipeline atopic dermatitis (AD) gene expression profile (GEP) test at the 25th Annual Fall Clinical Dermatology Conference®, taking place Oct. 23–26, 2025, in Las Vegas, Nevada. “The DecisionDx-Melanoma test has demonstrated clinically significant risk stratification of melanoma. This current study with 13,560 patients is unique in that the clinically relevant risk stratification was seen and reported across histological subtypes of melanoma,” said Etan Marks, D.O., board-certified pathologist, hematopathologist and dermatopath
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]Yahoo! Finance
- Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive YearGlobeNewswire
- New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 11/3/25 - Beat
CSTL
Sec Filings
- 12/4/25 - Form 4
- 12/1/25 - Form 4
- 11/26/25 - Form 4
- CSTL's page on the SEC website